The understanding of the mechanisms of alternative splicing and the occurrence of variant isoforms of CD44 is essential not only to a deeper insight into malignant progression but may also provide a new generation of splicing inhibitors as therapies for cancer (Bonnal et al., 2020; Rogalska et al., 2022). The gene discussed is CD44; the disease is cancer.